Inhibitory effects of nedocromil sodium on the in vitro induced migration and leukotriene formation of human granulocytes.

Abstract:

:Inflammatory cells, such as neutrophils and eosinophils, are thought to actively contribute to the pathogenesis of asthma since they infiltrate into the lung tissue and may be activated locally to release bronchoconstrictor mediators. In this study we provide evidence that nedocromil sodium is capable of effectively inhibiting the platelet-activating factor (PAF) and zymosan-activated serum (ZAS)-induced chemotaxis of polymorphonuclear granulocytes (PMN) [IC50 approximately 1 nmol/L and 0.1 mumol/L respectively]. The same inhibitory potency was obtained with sodium cromoglycate. Thus, nedocromil sodium may effectively inhibit the mobilisation of inflammatory cells in the lung. Furthermore, nedocromil sodium is capable of inhibiting the formation of the bronchoconstrictor mediator leukotriene-C4 (LTC4) by eosinophils in a concentration-dependent way [IC30 for A23187: 5.6 10(-5) mol/L; IC30 for opsonised zymosan (OZ): 6.3 10(-5) mol/L], whereas this drug is not capable of inhibiting leukotriene-B4 (LTB4) formation by neutrophils. These findings indicate that nedocromil sodium inhibits the release of bronchoconstrictor mediators not only from mast cells but also from eosinophils.

journal_name

Drugs

journal_title

Drugs

authors

Bruijnzeel PL,Warringa RA,Kok PT,Hamelink ML,Kreukniet J

doi

10.2165/00003495-198900371-00004

subject

Has Abstract

pub_date

1989-01-01 00:00:00

pages

9-18; discussion 69-77

eissn

0012-6667

issn

1179-1950

journal_volume

37 Suppl 1

pub_type

杂志文章

相关文献

DRUGS文献大全
  • Methylnaltrexone.

    abstract::Methylnaltrexone is a selective mu-opioid receptor antagonist that has restricted ability to cross the blood-brain barrier, thus enabling reversal of opioid-induced peripheral effects, such as constipation, without affecting the central effects, such as pain relief. Treatment with subcutaneous methylnaltrexone 0.15-0....

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11204520-000000000-00000

    authors: Garnock-Jones KP,McKeage K

    更新日期:2010-05-07 00:00:00

  • Oxatomide. A review of its pharmacodynamic properties and therapeutic efficacy.

    abstract::Oxatomide is an orally active H1-histamine receptor antagonist which, as appears to occur with some other antihistamines, also inhibits mast cell degranulation. Oxatomide has demonstrated response rates similar to those with other more established members of its drug class in a few studies of chronic urticaria and all...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198427030-00003

    authors: Richards DM,Brogden RN,Heel RC,Speight TM,Avery GS

    更新日期:1984-03-01 00:00:00

  • Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

    abstract::Gatifloxacin (Tequin) is an 8-methoxy fluoroquinolone approved in the US for use in the treatment of community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), acute sinusitis, uncomplicated and complicated urinary tract infections (UTIs), pyelonephritis, gonorrhoea and uncomplicated skin an...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565050-00007

    authors: Keam SJ,Croom KF,Keating GM

    更新日期:2005-01-01 00:00:00

  • A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls.

    abstract:BACKGROUND:Opioid pharmacotherapies play an important role in the treatment of opioid-dependent women; however, very little is known about the safety of naltrexone in pregnant patients. OBJECTIVE:This study examined the obstetric health of opioid-dependent women who were treated with implant naltrexone during pregnanc...

    journal_title:Drugs

    pub_type: 杂志文章,meta分析

    doi:10.1007/s40265-017-0762-9

    authors: Kelty E,Hulse G

    更新日期:2017-07-01 00:00:00

  • Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.

    abstract::Saxagliptin (Onglyza™) is a dipeptidyl peptidase 4 inhibitor widely approved for the treatment of type 2 diabetes mellitus. In the EU, saxagliptin is indicated as combination therapy with metformin, a sulfonylurea, a thiazolidinedione, or insulin (with or without metformin) for the treatment of adult patients with typ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11208160-000000000-00000

    authors: Yang LP

    更新日期:2012-01-22 00:00:00

  • Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use.

    abstract::Chenodeoxycholic acid (chenic acid; CDCA) is 1 of the 3 major biliary bile acids in man. When administered in pharmacological doses it causes a decrease in cholesterol saturation of bile, which in turn may lead to gradual dissolution of cholesterol gallstones. The stone dissolution rate during CDCA therapy has varied ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198121020-00002

    authors: Iser JH,Sali A

    更新日期:1981-02-01 00:00:00

  • Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments.

    abstract::Non-insulin-dependent diabetes mellitus (NIDDM, type 2 diabetes) is a heterogeneous disease resulting from a dynamic interaction between defects in insulin secretion and insulin action. There are various pharmacological approaches to improving glucose homeostasis, but those currently used in clinical practice either d...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199754030-00001

    authors: Scheen AJ

    更新日期:1997-09-01 00:00:00

  • Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products.

    abstract::Through years of evolutionary selection pressures, organisms have developed potent toxins that coincidentally have marked antineoplastic activity. These natural products have been vital for the development of multiagent treatment regimens currently employed in cancer chemotherapy, and are used in the treatment of a va...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0489-4

    authors: Trendowski M

    更新日期:2015-11-01 00:00:00

  • ZD1839 ('Iressa') as an anticancer agent.

    abstract::ZD1839 ('Iressa') is an orally active, selective epidermal growth factor receptor-tyrosine kinase inhibitor which blocks signal transduction pathways implicated in the proliferation and survival of cancer cells and other host-dependent processes promoting cancer growth. In preclinical studies, ZD1839 produced reversib...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060001-00004

    authors: Baselga J,Averbuch SD

    更新日期:2000-01-01 00:00:00

  • JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.

    abstract::The Janus kinase/signal transduction and activator of transcription (JAK-STAT) signaling pathway is implicated in the pathogenesis of inflammatory and autoimmune diseases including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Many cytokines involved in the pathogenesis of autoimmune and inflammator...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0701-9

    authors: Banerjee S,Biehl A,Gadina M,Hasni S,Schwartz DM

    更新日期:2017-04-01 00:00:00

  • Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections.

    abstract::Cefixime is an orally active third generation cephalosporin with in vitro antibacterial activity against most important lower respiratory pathogens. The drug is active against Haemophilus influenzae, Moraxella catarrhalis and penicillin-susceptible Streptococcus pneumoniae but not Staphylococcus aureus. Cefixime has a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549060-00010

    authors: Markham A,Brogden RN

    更新日期:1995-06-01 00:00:00

  • Diquafosol ophthalmic solution 3 %: a review of its use in dry eye.

    abstract::Diquafosol ophthalmic solution 3 % (Diquas(®)) is a P2Y2 receptor agonist that promotes tear fluid and mucin secretion and is currently approved in Japan and South Korea for the treatment of dry eye. In randomized, double-blind, multicentre trials in patients with dry eye, significantly greater improvements in fluores...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0409-7

    authors: Keating GM

    更新日期:2015-05-01 00:00:00

  • Is tiaprofenic acid different from other NSAIDs with regard to effects on renal function in the elderly?

    abstract::In a study of the effects of various NSAIDs on renal function in the elderly, indomethacin, tiaprofenic acid and sulindac were administered to patients ranging in age from 54 to 97 years for a period of 3 months. Indomethacin sustained release (25 mg tid) was administered to 66 patients, tiaprofenic acid (200 mg tid) ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198800351-00022

    authors: Ishioka T

    更新日期:1988-01-01 00:00:00

  • Drug treatment of scleroderma.

    abstract::Scleroderma or systemic sclerosis is a rare condition with many clinical manifestations including Raynaud's phenomenon. As with many other rarely encountered diseases, drug therapy for scleroderma is often empirical with little evidence in the form of randomised controlled trials to aid drug choice. Raynaud's phenomen...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161030-00008

    authors: Leighton C

    更新日期:2001-01-01 00:00:00

  • Osteoarthritis 1991. Current drug treatment regimens.

    abstract::Osteoarthritis, the most common rheumatic disease, presents the clinician with a major therapeutic and management task. The chronic and progressive course of the disease is punctuated by pain, declining function and escalating disability. This article attempts to deal with the pharmacological therapeutic options avail...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199141020-00005

    authors: al Arfag A,Davis P

    更新日期:1991-02-01 00:00:00

  • Drugs for cardiovascular disease prevention in women: implications of the AHA Guidelines--2007 Update.

    abstract::Lifestyle interventions constitute the initial strategy for the primary and secondary prevention of cardiovascular disease in women. However, pharmacotherapy is often indicated for control of major cardiovascular risk factors, and abundant clinical trial data support the morbidity and mortality benefit of a number of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868030-00006

    authors: Wenger NK

    更新日期:2008-01-01 00:00:00

  • Candesartan cilexetil: an update of its use in essential hypertension.

    abstract:UNLABELLED:Candesartan cilexetil is converted to the angiotensin II receptor antagonist candesartan during absorption from the gastrointestinal tract. The selective and competitive binding of candesartan to the angiotensin II type 1 (AT(1)) receptor prevents binding of angiotensin II, a key mediator in the renin-angiot...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262080-00016

    authors: Easthope SE,Jarvis B

    更新日期:2002-01-01 00:00:00

  • Oral etoposide in lymphoma.

    abstract::Etoposide is one of the most active agents for the therapy of lymphomas. Oral etoposide has proven to be active in and clearly beneficial for patients with previously treated lymphomas. The optimal dose and schedule of oral etoposide for use in combination chemotherapy are still uncertain, but low daily doses (50 to 1...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958003-00006

    authors: Greco FA

    更新日期:1999-01-01 00:00:00

  • Pharmacotherapy for overactive bladder: an evidence-based approach to selecting an antimuscarinic agent.

    abstract::Multiple drugs are now available for the treatment of overactive bladder. Currently, the pharmacological approach is to deal with the problem at the neuromuscular junction by attempting to stop the activity of the neurotransmitter with antimuscarinic medications. This article reviews the positive and negative aspects ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666100-00005

    authors: Appell RA

    更新日期:2006-01-01 00:00:00

  • Nivolumab: a review of its use in patients with malignant melanoma.

    abstract::Nivolumab (Opdivo(®)) is a fully human monoclonal antibody against programmed death receptor-1, a negative regulatory checkpoint molecule with a role in immunosuppression. The drug is administered intravenously and is approved for the treatment of unresectable malignant melanoma in Japan. The potential for intravenous...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0234-4

    authors: Deeks ED

    更新日期:2014-07-01 00:00:00

  • Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders.

    abstract::Goserelin is a gonadotrophin-releasing hormone (GnRH) analogue which, during continuous administration, down-regulates the pituitary-ovarian gonadal axis and reduces levels of the gonadotrophins, luteinising hormone and follicle-stimulating hormone. In women, this results in suppression of ovarian steroidogenesis and ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199651020-00009

    authors: Perry CM,Brogden RN

    更新日期:1996-02-01 00:00:00

  • New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship.

    abstract::A gradual rise in drug-resistant trends among Gram-negative organisms, especially carbapenem-resistant (CR) Enterobacteriaceae (CRE), CR-Pseudomonas aeruginosa, and extensively-drug-resistant (XDR) Acinetobacter baumannii, poses an enormous threat to healthcare systems worldwide. In the last decade, many pharmaceutica...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01112-1

    authors: Jean SS,Gould IM,Lee WS,Hsueh PR,International Society of Antimicrobial Chemotherapy (ISAC).

    更新日期:2019-05-01 00:00:00

  • Corticosteroids and adrenal suppression. Characterising and avoiding the problem.

    abstract::Glucocorticoids are used for a variety of illnesses. One of their major complications is suppression of the hypothalamic-pituitary-adrenal axis, rendering a patient unable to respond to stress. The risk of this suppression may be minimised by the use of short-acting glucocorticoid preparations, administration of the e...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198938050-00008

    authors: Helfer EL,Rose LI

    更新日期:1989-11-01 00:00:00

  • A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee.

    abstract:UNLABELLED:Joint pain is the main complaint in patients affected by osteoarthritis (OA), and NSAIDs are commonly used to treat pain associated with OA. Over the past few years, cyclo-oxygenase (COX)-2-selective inhibitors have been proved to have certain advantages over non-selective NSAIDs and have been increasingly u...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-200363001-00006

    authors: Bianchi M,Broggini M

    更新日期:2003-01-01 00:00:00

  • Comparative efficacy of cyclandelate versus flunarizine in the prophylactic treatment of migraine.

    abstract::In a double-blind, parallel-group randomised trial of 3 months' duration, the efficacy of cyclandelate 800 mg twice daily in migraine prophylaxis was compared with that of flunarizine 5mg daily in 40 patients. In comparison with placebo and baseline values, both drugs significantly relieved symptoms of migraine as ass...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198700332-00019

    authors: Nappi G,Sandrini G,Savoini G,Cavallini A,de Rysky C,Micieli G

    更新日期:1987-01-01 00:00:00

  • Optimum management of postoperative pain.

    abstract::After surgery, patients try to minimise discomfort by various manoeuvres including change of posture, immobilisation of injured areas and use of analgesic drugs. The characteristic finding with drug use, revealed by permitting patients to titrate themselves with analgesic from a machine, is that the interindividual do...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198529040-00004

    authors: Bullingham RE

    更新日期:1985-04-01 00:00:00

  • Acamprosate: A Review of Its Use in Alcohol Dependence.

    abstract::Acamprosate (Campral(®), Aotal(®), Regtect(®)) is one of a limited number of pharmacological treatment options approved as an adjunct to psychosocial interventions to facilitate the maintenance of abstinence in alcohol-dependent patients. It has been used in Europe, the USA and other countries for many years and was r...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0423-9

    authors: Plosker GL

    更新日期:2015-07-01 00:00:00

  • Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression.

    abstract::Alprazolam is a triazolobenzodiazepine which is related to diazepam and other 1,4-benzodiazepines, and has a similar pharmacological profile. Relative to the newer benzodiazepines, alprazolam has an intermediate half-life of 10 to 12 hours in healthy young subjects. In placebo-controlled and double-blind comparative t...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-198427020-00002

    authors: Dawson GW,Jue SG,Brogden RN

    更新日期:1984-02-01 00:00:00

  • Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.

    abstract::Pegylation of interferon-alpha-2a is associated with improved sustained virological response rates in patients with chronic hepatitis C. Subsequently, combination therapy with peginterferon-alpha-2a (40kD) [Pegasys] and ribavirin (Copegus trade mark, Rebetol) was investigated to establish if the efficacy of peginterfe...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363070-00008

    authors: Keating GM,Curran MP

    更新日期:2003-01-01 00:00:00

  • Activity of cefotaxime and amikacin against 14,272 gram-negative bacteria from clinical samples in the period 1980 to 1985.

    abstract::The sensitivity to cefotaxime and amikacin of 14,272 Gram-negative bacilli (Enterobacteriaceae and non-fermenting Gram-negative bacilli) isolated from clinical samples was studied during the period 1980 to 1985. The minimum inhibitory concentration (MIC) was determined by means of diffusion in agar. Strains were consi...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198800352-00003

    authors: Dámaso D,Sánchez-Moreno MP,Martínez-Martínez L,Mesa E,Portero F,Mendaza P,Daza RM

    更新日期:1988-01-01 00:00:00